





EB-1A RFE Risk Assessment Report

Date: 2025-07-28 17:19

Table of Contents

-  Risk Matrix
-  Rule-Based Findings
-  Repetitive Letters
-  Recommendations

Risk Matrix

Criterion	Risk Level	Issues Detected
Criterion 1	High	4
Criterion 4	High	5
Criterion 3	High	5
Criterion 5	High	5

Rule-Based Findings

Criterion 1

Dr. Mendes received the 2022 American Cancer Society Excellence Award in Translational Research. This national award is presented annually to three outstanding researchers and includes a peer-review selection process. The award was

announced on the ACS website and covered in several academic news...

- Missing expected detail: award name
- Missing expected detail: international
- Missing expected detail: competition
- Missing expected detail: number of recipients

Criterion 4

Dr. Mendes received the 2022 American Cancer Society Excellence Award in Translational Research. This national award is presented annually to three outstanding researchers and includes a peer-review selection process. The award was announced on the ACS website and covered in several academic news...

- Judging activity lacks professional/peer-reviewed status.
- Missing expected detail: journal name
- Missing expected detail: review confirmation
- Missing expected detail: conference name
- Missing expected detail: dissertation

Criterion 3

Science Today published a full-length interview titled "Molecular Frontiers with Dr. Mendes" covering his innovations in RNA therapeutics. Additionally, The Lancet Oncology

- Missing expected detail: publication title
- Missing expected detail: media name
- Missing expected detail: author
- Missing expected detail: date
- Missing expected detail: quote about applicant

Criterion 5

Science Today published a full-length interview titled "Molecular Frontiers with Dr. Mendes" covering his innovations in RNA therapeutics. Additionally, The Lancet Oncology

- Missing expected detail: citation count
- Missing expected detail: h-index
- Missing expected detail: patent
- Missing expected detail: letter of impact
- Missing expected detail: commercial use

Repetitive Recommendation Letters

No significant repetition detected.

Editable Recommendations

Fix for Criterion 1:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 4:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 3:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."

Fix for Criterion 5:

"Consider rephrasing the excerpt to explicitly state the impact, significance, or national/international recognition."